Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study

Petrioli, Roberto; Frediani, Bruno; Manganelli, Antonio; Barbanti, Gabriele; Capua, Bruno De; Lauretis, Angelo De; Salvestrini, Franco; Mondillo, Sergio; Francini, Guido

doi:10.1002/(sici)1097-0142(19960115)77:2<344::aid-cncr18>3.0.co;2-1

Cited by 161 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, cisplatin in combination with etoposide and bleomycin is considered a curative treatment for testicular cancer and is beneficial in combination regimens for ovarian cancer and cancers of the bladder, head and neck, endometrium, esophagus, and lung (12)(13)(14)(15). Our data provide the first step in identifying heritable genes that put patients at Fig.…”

Section: Discussionmentioning

confidence: 84%

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

et al. 2004

View full text Add to dashboard Cite

Little is known about the genetic determinants explaining variation in sensitivity to chemotherapeutic cytotoxicity. We characterized the degree of cisplatin sensitivity, using lymphoblastoid cell lines derived from 10 Centre d'Etude du Polymorphisme Humain pedigrees. We estimated the heritability for susceptibility to cisplatin-induced cytotoxicity to be ϳ0.47; therefore, sensitivity to the cytotoxic effects of cisplatin is under appreciable genetic influence. Linkage analysis was performed, and the strongest signal (lod score, 2.16; empirical P ‫؍‬ 0.0005) was found on chromosome 1 at 44 cM. Susceptibility to cisplatin-induced cytotoxicity is likely due to multiple loci, with low locus-specific heritability contributing to the trait. These data show the power of using large pedigrees that have been extensively genotyped for evaluating the genetic contribution to sensitivity to cell growth inhibition by anticancer agents.

show abstract

Section: Discussionmentioning

confidence: 84%

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, carboplatin-based and other noncisplatin based regimens are widely considered to be inferior to MVAC and gemcitabine-cisplatin. 12,[19][20][21] For example, in a randomized trial of MVAC versus methotrexate-vinblastine-carboplatin in patients with metastatic UC, a significantly reduced cancer-specific survival was seen in patients receiving methotrexate-vinblastine-carboplatin (median 9 vs 16 months, P ¼ .03). 19 A single-study arm phase 2 trial of neoadjuvant paclitaxel-gemcitabine-carboplatin for muscleinvasive UC of the bladder also reported fewer pathologic complete responses than had been reported in other trials of neoadjuvant CBCC in similar patients.…”

Section: Discussionmentioning

confidence: 99%

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Lane

Smith

Larson

et al. 2010

Cancer

195

117

View full text Add to dashboard Cite

BACKGROUND:The prevalence of chronic kidney disease (CKD) in patients with upper tract urothelial carcinoma (UTUC) is poorly defined, both before and after nephrouretectomy. Although multimodal treatment paradigms for UTUC are under‐developed, this has important implications on patients' ability to receive cisplatin‐based combination chemotherapy (CBCC).METHODS:Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula in 336 patients with UTUC, who were treated at the Cleveland Clinic by nephroureterectomy since 1992. An eGFR cutoff of 60 mL/min/1.73 m2 was used to determine the presence of CKD and eligibility for CBCC.RESULTS:Median age was 72 years and median preoperative eGFR was 59 mL/min/1.73m2. Before nephroureterectomy, only 48% of patients were eligible to receive CBCC and this decreased to 22% postoperatively (P < .001). In the 144 patients with pT2‐pT4 and/or pN1‐pN3 disease who are suitable to receive CBCC, these proportions were 40% and 24%, respectively (P = .009). Although 50 patients overall received some form of perioperative chemotherapy, only 3 and 11 patients received neoadjuvant and adjuvant CBCC, respectively.CONCLUSIONS:CKD is prevalent in the UTUC population and a minority of patients has an optimal eGFR to receive neoadjuvant CBCC. Nephrouretectomy may eliminate CBCC as a therapeutic option in 49% of high‐risk patients if it is deferred to the adjuvant setting. Multimodal treatment strategies for UTUC should focus on neoadjuvant chemotherapy, as few patients are eligible for adjuvant CBCC because of the substantial decline in eGFR caused by nephroureterectomy. Cancer 2010. © 2010 American Cancer Society.

show abstract

“…Phase II trials of carboplatin, as a substitution for cisplatin in first-line chemotherapy regimens, demonstrated that carboplatin-based therapy was less effective than cisplatin-based therapy. However, there is few data on carboplatin as a substitution for cisplatinbased therapy in second-line chemotherapy (Petrioli et al, 1996;Bellmunt et al, 1997). Randomised trials with carboplatin-based regimens in patients who failed first-line platinum-based chemotherapy and development of new combinations consisting of safer and more effective agents is needed for the treatment of patients with depleted marrow reserves and impaired renal function after the failure of first-line chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

et al. 2007

View full text Add to dashboard Cite

We investigated the safety and efficacy of a methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) combination regimen as second-line chemotherapy for patients with advanced or metastatic transitional cell carcinoma who failed first-line gemcitabine and cisplatin (GC) chemotherapy. Thirty patients who had progressed or relapsed after GC chemotherapy as first-line treatment were enrolled in this study. The major toxicities were neutropaenia and thrombocytopaenia. A grade 3 or 4 neutropaenia occurred in 19 (63.3%) and a grade 3 or 4 thrombocytopaenia developed in nine patients (30.0%). There were no life-threatening complications during the study. The overall response was 30%. A complete response was achieved in two patients (6.7%) and a partial response in seven (23.3%). The overall disease control rate was 50%. Seven out of 16 patients who had responded previously to GC responded to M-VAC, while 2 out of 14 who had not responded to GC responded to M-VAC. The median response duration was 3.9 months and the median progression-free survival was 5.3 months. The median overall survival was 10.9 months. M-VAC showed encouraging efficacy and reversible toxicities in patients who had progressed after GC chemotherapy and, especially, M-VAC appears to be a reasonable option as a sequential treatment regimen in patients who responded previously to GC chemotherapy.

show abstract

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study

Abstract: M-VECa has a low level of gastrointestinal, renal, neurologic, and otologic toxicity, but is apparently less effective than M-VEC in the treatment of recurrent or metastatic bladder cancer. However, a larger, randomized Phase III trial is needed to confirm these results.

Cited by 161 publications

References 28 publications

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

Contact Info

Product

Resources

About